RxDoctor Payments Data

Anthony Capobianco, PA

Physician Assistant · Hamden, CTNPI 1659352482

Payments from drug & device makers

$6,097in general payments, 2019–2025

Across 301 payments — averaging $20.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Gilead$1K
  • Ardelyx, Inc.$249
  • Madrigal Pharmaceuticals$244
  • Ironwood Pharmaceuticals, Inc$226
  • QOL Medical, LLC$169
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$6,097100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,097 in reported general payments places this provider in the 95th percentile of 1,795 physician assistant providers in Connecticut.

See all physician assistant providers in Connecticut

Medicare billing

Part B allowed, 2024
$23,881
Medicare patients
193
Services billed
268

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin25$84,910
LinzessLinaclotide84$70,945
OzempicSemaglutide32$32,540
CreonLipase/Protease/Amylase15$22,615
RybelsusSemaglutide16$15,649
MotegrityPrucalopride Succinate18$13,912
ClenpiqSod Picosulf/Mag Ox/Citric Ac59$10,251
Mesalamine11$9,916
Dexlansoprazole DrDexlansoprazole29$5,917
Ursodiol15$3,523
Omeprazole189$3,286
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C19$2,788
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates39$2,346
Pantoprazole Sodium174$2,239
Sucralfate12$1,374

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$2,812$93,56099 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu$153$87,69744 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$166$13,91218 claims
Ferring Pharmaceuticals Inc.Clenpiq$36$10,25159 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,795 physician assistant providers in Connecticut.

Other physician assistant in Hamden

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →